mRNA-1283
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Trade names | mNEXSPIKE[1] |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| COVID-19 portal |
mRNA-1283, sold under the brand name mNEXSPIKE, is a COVID-19 vaccine candidate developed by Moderna.[2][3][4]
Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers.[5] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[6]
- ^ "Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it". CBS News. 31 May 2025. Retrieved 26 June 2025.
- ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
- ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
- ^ "Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it". CBS News. 31 May 2025. Archived from the original on 26 June 2025. Retrieved 26 June 2025.
- ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
- ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.